[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
August 9, 2000

Surgical Sealant for Lung Cancer

JAMA. 2000;284(6):685. doi:10.1001/jama.284.6.685

The FDA has approved FocalSeal-L (Focal Inc, Lexington, Mass) for use in lungs as an adjunct to standard closure of pleural air leaks incurred during elective pulmonary resection, such as the removal of cancerous lung tumors.

The new product, which received expedited review by the FDA, consists of synthetic absorbable sealant and primer solutions that are applied to the target tissue site as liquids. Upon exposure to blue-green light, the primer and sealant solutions polymerize to form a cross-linked, clear, flexible, adherent hydrogel network.

First Page Preview View Large
First page PDF preview
First page PDF preview
×